AbCellera Biologics Inc. (ABCL) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value (m); Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $61.16M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | (m) | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Deferred revenue · latest quarter (USD) | $61.16M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $20.70M + $40.45M ≈ $61.16M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $9.71M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $9.71M − $0.00 ≈ $9.71M |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 411.56M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities |
| Amounts owed to suppliers | (m) | |
| Total deferred revenue | 61.16M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | 20.70M USD | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | 40.45M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 9.71M USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability · Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $9.71M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $135.62M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $61.16M | (m) | $9.71M | $411.56M | (m) | $20.70M | $40.45M | $9.71M | $0.00 |
| 2026-03-31 | (m) | (m) | $8.99M | (m) | $10.07M | $369.03M | (m) | $7.74M | $1.25M | $11.32M | $1.25M |
| 2025-12-31 | (m) | (m) | $17.03M | (m) | $1.27M | $390.05M | (m) | $13.53M | $3.50M | $4.77M | $3.50M |
| 2025-09-30 | (m) | (m) | $21.54M | (m) | $1.39M | $391.95M | (m) | $15.69M | $5.85M | $1.39M | $0.00 |
| 2025-06-30 | (m) | (m) | $28.58M | (m) | $1.56M | $394.99M | (m) | $16.95M | $11.63M | $1.56M | $0.00 |
| 2025-03-31 | (m) | (m) | $32.53M | (m) | $1.62M | $321.23M | (m) | $18.79M | $13.75M | $1.62M | $0.00 |
| 2024-12-31 | (m) | (m) | $19.22M | (m) | $1.47M | $304.47M | (m) | $13.52M | $5.70M | $1.47M | $0.00 |
| 2024-09-30 | (m) | (m) | $13.68M | (m) | $1.52M | $314.73M | (m) | $5.58M | $8.10M | $1.52M | $0.00 |
| 2024-06-30 | (m) | (m) | $14.37M | (m) | $6.35M | $301.51M | (m) | $6.40M | $7.97M | $6.35M | $0.00 |
| 2024-03-31 | (m) | (m) | $19.14M | (m) | $5.74M | $333.18M | (m) | $10.56M | $8.57M | $5.74M | $0.00 |
| 2023-12-31 | (m) | (m) | $27.15M | (m) | $5.91M | $335.78M | (m) | $18.96M | $8.20M | $5.91M | $0.00 |
| 2023-09-30 | (m) | (m) | $33.89M | (m) | $5.05M | $329.42M | (m) | $17.51M | $16.38M | $5.05M | $0.00 |
| 2023-06-30 | (m) | (m) | $36.26M | (m) | $2.33M | $342.34M | (m) | $8.54M | $27.72M | $2.33M | $0.00 |
| 2023-03-31 | (m) | (m) | $37.22M | (m) | $2.96M | $289.42M | (m) | $11.81M | $25.42M | $2.96M | $0.00 |
| 2022-12-31 | (m) | (m) | $41.13M | (m) | $3.09M | $307.63M | (m) | $21.61M | $19.52M | $3.09M | $0.00 |
| 2022-09-30 | (m) | (m) | $30.92M | (m) | $-21.25M | $302.24M | (m) | $6.82M | $24.11M | $2.86M | $24.11M |
| 2022-06-30 | (m) | (m) | $32.00M | (m) | $-24.40M | $380.93M | (m) | $4.62M | $27.38M | $2.98M | $27.38M |
| 2022-03-31 | (m) | (m) | $35.86M | (m) | $-23.24M | $384.78M | (m) | $9.19M | $26.67M | $3.43M | $26.67M |
| 2021-12-31 | (m) | (m) | $34.95M | (m) | $-25.68M | $292.84M | (m) | $7.54M | $27.42M | $1.73M | $27.42M |
| 2021-09-30 | (m) | (m) | $35.35M | (m) | $-27.48M | $219.34M | (m) | $6.17M | $29.18M | $1.70M | $29.18M |
| 2021-06-30 | (m) | (m) | $31.23M | (m) | $-19.01M | $184.18M | (m) | $10.57M | $20.66M | $1.66M | $20.66M |
| 2021-03-31 | (m) | (m) | $32.38M | (m) | $-20.14M | $171.40M | (m) | $11.31M | $21.07M | $931.00K | $21.07M |
| 2020-12-31 | (m) | (m) | $26.23M | (m) | $-13.02M | $175.03M | (m) | $6.59M | $19.64M | $6.62M | $19.64M |
| 2020-09-30 | (m) | (m) | $26.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $28.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $28.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $5.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |